Plain-English translation of NCT06267274 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a generic version of bimatoprost eye drops works as well as the brand-name version (LUMIGAN®) in treating glaucoma and high eye pressure. Both versions contain the same active ingredient, but researchers want to confirm they work equally well and are equally safe in real patients.
Generic medications are less expensive than brand-name versions, but regulators need to prove they work just as well. This trial will give doctors and patients confidence that the generic eye drop is a reliable, cost-effective option for managing glaucoma.
You likely qualify if…
You likely don't qualify if…
You will first be screened to make sure you qualify, then stop taking your current eye pressure medications for 1–4 weeks. You'll then be randomly assigned to use either the generic or brand-name eye drop in both eyes. The study lasts 6 weeks, with visits at 2 weeks and 6 weeks where doctors will measure your eye pressure at different times of day. Researchers will also track any side effects you experience.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States